Search
for
Sort by
Research 61–90 of 1000+
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Advances in the mechanism and new therapies of alopecia areata
- Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature
- Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata
- 33774 Baricitinib results in eyebrow and eyelash growth in patients with alopecia areata who do not achieve 20% or less scalp hair loss
- 44182 Treatment with Oral Janus Kinase Inhibitors in Adults Patients with Alopecia Areata: A Systematic Review and Meta-Analysis
- Alopecia Universalis Treated With Tofacitinib: The Role of JAK/STAT Inhibitors in Hair Regrowth
- Treatment Response to JAK Inhibitors in Long-standing Alopecia Areata (≥8 Years): A Real-world Observational Study
- Public Interest in Janus Kinase (JAK) IInhibitors for Alopecia Areata: A Google Trend Analysis
- Ritlecitinib in Alopecia Areata: A 24‐Week Real‐World Experience Contrasting JAK Inhibitor‐Naïve and JAK Inhibitor‐Experienced Patients
- Medical Therapies
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- 290 Brepocitinib improves cicatricial alopecia and downregulates key T-helper biomarkers
- The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases
- Safety and efficacy of tofacitinib in 97 alopecia areata patients
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- Comparative efficacy of Janus kinase inhibitors in severe alopecia areata: a network meta-analysis based on randomized controlled trials
- Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series
- Baricitinib for alopecia areata
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Baricitinib: A Review in Severe Alopecia Areata
- Netherton syndrome subtypes share IL-17/IL-36 signature with distinct IFN-α and allergic responses
- Personalized Medicine in the Field of Inflammatory Skin Disorders
- Efficacy of JAK inhibitors in the treatment of alopecia: A case report of 10 patients
- Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
- A Case of Tofacitinib for the Treatment of Resistant Vitiligo and Sustained Repigmentation After Discontinuation
- Treatment of moderate-to-severe alopecia areata in adolescents with baricitinib: A retrospective review of 29 patients
- An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
- Alopecia Areata